Allena Pharmaceuticals, Inc.
Allena is currently enrolling in a Phase 2 clinical trial of ALLN-177 to evaluate the efficacy and safety of ALLN-177 in adult patients with secondary hyperoxaluria.
For more information about these clinical trials and for participating research centers, visit www.clinicaltrials.gov and search for “ALLN-177” or contact Premier Research by phone 1-800-961-4641 or email: Allena.Studies@premier-research.com
About Post Author
